Regeneron: Strong Financial Performance and Future Growth Potential Drive Buy RatingWe will know more by late November (the original PDUFA), as there are multiple scenarios which depend on the FDA issuing a CRL and overall flexibility.Global The COPD And CSU As discussed here, Q3 WW Dupi sales were $4.86B (+12% Q/Q; +27% Y/Y), which were 5% above consensus. Dupi continues to hold the #1 share of TRx share across all established indications (AD, asthma, CRSwNP, EoE, and PN). Demand continues to drive sales growth, with Regeneron reporting that over 1.3MM patients globally are on Dupi.